Toviaz(fesoterodine)
Fesoterodine, Toviaz (fesoterodine) is a small molecule pharmaceutical. Fesoterodine was first approved as Toviaz on 2007-04-20. It is used to treat urge urinary incontinence in the USA. It has been approved in Europe to treat overactive urinary bladder.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Fesoterodine, Toviaz (discontinued: Fesoterodine)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fesoterodine fumarate | ANDA | 2025-06-17 |
| toviaz | New Drug Application | 2024-12-12 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| urge urinary incontinence | EFO_0006865 | D053202 | N39.41 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FESOTERODINE FUMARATE, TOVIAZ, PFIZER | |||
| 2024-12-17 | PED | ||
| 2024-06-17 | I-861 | ||
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 9 | 4 | 13 | 15 | 14 | 55 |
| Urinary incontinence | D014549 | — | R32 | 2 | 1 | 1 | 3 | 1 | 8 |
| Enuresis | D004775 | — | R32 | — | 1 | 1 | 2 | — | 4 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | 1 | — | 1 | 1 | — | 3 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
| Adenocarcinoma | D000230 | — | — | — | — | — | 1 | — | 1 |
| Urinary bladder neck obstruction | D001748 | EFO_1000840 | N32.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | — | 3 | — | — | 3 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | 2 | — | — | 2 |
| Nocturia | D053158 | — | R35.1 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | — | — | — | 1 |
| Autonomic dysreflexia | D020211 | EFO_1001762 | G90.4 | — | 1 | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
| Stress urinary incontinence | D014550 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Food | D005502 | — | STY/T168 | 1 | — | — | — | — | 1 |
| Radiation injuries | D011832 | — | T66 | 1 | — | — | — | — | 1 |
| Cystitis | D003556 | EFO_1000025 | N30 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
| Urologic diseases | D014570 | — | N39.9 | — | — | — | — | 1 | 1 |
| Urinary bladder diseases | D001745 | — | N32.9 | — | — | — | — | 1 | 1 |
| Deprescriptions | D000069340 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fesoterodine |
| INN | fesoterodine |
| Description | Fesoterodine is a diarylmethane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 286930-02-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201764 |
| ChEBI ID | — |
| PubChem CID | 6918558 |
| DrugBank | DB06702 |
| UNII ID | 621G617227 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Toviaz – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Fesoterodine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 760 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,554 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use